Principal Investigator

Awardee Organization

Purdue University
United States

Fiscal Year
Activity Code
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Point-of-care screening test for early cervical cancer detection

Although cervical cancer is an easily curable disease if detected early, it continues to claim the lives of hundreds of thousands of women worldwide. Healthcare disparities have resulted in cervical cancer incidence and mortality that are five times higher in low and middle income countries (LMICs) than in high-income countries. In the United States, cervical cancer mortality rates are twice as high among rural women than their urban counterparts. The wide disparity in cervical cancer incidence rates and deaths is attributed to both higher HPV infection rates and a lack of accessible screening and treatment of pre-invasive cervical lesions. The current standard of care in the US, a cytology-based Pap smear, requires resource intensive laboratory and clinical specialists with a long turnaround time from sample collection to result. Alternatives, such as visual inspection with acetic acid and emerging HPV-targeted tests, have poor specificity for cervical cancer, leading to overtreatment that can cause complications including infertility and pre-term births and that further the burden on limited healthcare resources. This proposal aims to create an integrated point-of-care screening test that can be used by healthcare providers in under-resourced settings to obtain relevant clinical insights, including cervical cancer risk stratification, and enable same-visit treatment of high risk cervical lesions. Building on our preliminary development of a highly sensitive paper-based immunoassay to test for the key cervical cancer biomarker, valosin containing protein (VCP), the objective of this proposal is to combine VCP detection with three other known cervical cancer protein biomarkers, in a sensitive and specific single-step pointof-care assay. Specific milestones include: 1) Integrating and optimizing multiplex detection of cervical cancer biomarkers into a simple paper-based sample-to-answer device. 2) Evaluating the operational and performance metrics of the test in retrospective cervical swab samples. The outcome of this proposal will be a highly characterized point-of-care test with high sensitivity (95%) and specificity (90%) to detect high-risk cervical intraepithelial neoplasia and invasive cervical cancer within 40 minutes. This affordable solution for cervical cancer screening and control programs will be applicable in LMICs and will provide highly sensitive monitoring of cervical intraepithelial neoplasia in the US, where it will be especially impactful in high-risk populations that are currently underserved by existing screening programs.


  • Newsham EI, Phillips EA, Ma H, Chang MM, Wereley ST, Linnes JC. Characterization of wax valving and μPIV analysis of microscale flow in paper-fluidic devices for improved modeling and design. Lab on a chip. 2022 Jul 12;22(14):2741-2752. PMID: 35762978
  • Rodriguez NM, Burleson G, Linnes JC, Sienko KH. Thinking Beyond the Device: An Overview of Human- and Equity-Centered Approaches for Health Technology Design. Annual review of biomedical engineering. 2023 Jun 8;25:257-280. Epub 2023 Apr 17. PMID: 37068765
  • Ma H, Wereley ST, Linnes JC, Kinzer-Ursem TL. Measurement of Protein-Protein Interaction Dynamics Using Microfluidics and Particle Diffusometry. Analytical chemistry. 2022 Nov 15;94(45):15655-15662. Epub 2022 Oct 31. PMID: 36316007